The top 100 biopharmaceutical industrial parks in 2020 were announced, accounting for 40 seats in these three provinces.

Pharmaceutical Network Market Analysis" The biopharmaceutical industry has the characteristics of high technology, high input, high risk, high added value, long cycle and multidisciplinary intersection, so it determines the characteristics of its cluster developmentIn the form of park gathering, biopharmaceutical enterprises can quickly access technology, capital, talent and other resources to achieve better developmentAccording to the 2020 China Biopharmaceutical Industry Park Development Prospects and Investment Research Report released by the China Business Industry Research Institute, the total industrial output value of China's Biopharmaceutical Industrial Park reached 1.82 trillion yuan in 2018, up 16.95 percent year-on-yearAccording to preliminary statistics, the total output value of China's biopharmaceutical industrial park exceeded 2 trillion yuan in 2019can be said that the biopharmaceutical industrial park is gradually becoming an important support for the development of China's biopharmaceutical industry, and become an important carrier for integrating all kinds of innovative resourcesSo, what is the competitiveness of biopharmaceutical industrial parks everywhere? Recently, the Ministry of Industry and Information Technology Sadie consultants and Sina Pharmaceuticaljoint jointly released the "2020 Biopharmaceutical Industrial Park Top 100 List."list through 387 national industrial parks, including 168 national high-tech zones and 219 national-level economic zones in 2020 biopharmaceutical industry strength of the comprehensive assessment, the final formation of a top 100 list, with a view to providing decision-making support for local investment institutions and enterprisesit is understood that the list from 3 levels, 6 dimensions, 13 indicators of the biopharmaceutical industrial park's comprehensive competitiveness assessmentAmong them, the internal driving force is mainly evaluated through the three dimensions of aggregation effect, factor support and ability, the external driving force is the external stimulus factor of the development of the park, mainly involves the two dimensions of location transportation and surrounding environment, and the expansion potential mainly evaluates the enterprise saturation in the park, which is the direct embodiment of the park's future spatial expansion capacityas a whole, China's top 100 biomedicine parks, Shanghai Zhangjiang High-tech Industrial Development Zone ranked first, in addition, Jiangsu, Shandong and Guangdong Province, the construction of biopharmaceutical industrial parks in the first, a total of 40 parks were selected in the list of the top 100 biomedicine parksspecifically, Jiangsu Province was selected in the top 100 parks including Suzhou Industrial Park, Lianyungang High-tech Industrial Development Zone, Taizhou Pharmaceutical High-tech Industrial Development Zone, Wuzhong Economic and Technological Development Zone, Suzhou High-tech Industrial Development Zone and so onAmong them, Suzhou Industrial Park ranked second in the listLianyungang High-tech Industrial Development Zone and Taizhou Pharmaceutical High-tech Industrial Development Zone are also ranked in the top 10, ranking fourth and eighth respectively, Suzhou Industrial Park is home to a number of well-known biopharmaceutical companies and has excelledIn the recent short two days, Suzhou Industrial Park has 2 macromolecules, 2 small molecules of anti-cancer drugs out of good newsOn June 19th, Xinda Bio in Suzhou Biopharmaceutical Industry Park announced that the second monoclonal antibody anti-cancer drug Dayu was approved for listing, Hengrui Pharma's PD-1 monoanti-Irica was approved for two new indications, and the listing license application of Baiji Shenzhou Baiyue Ze (Zebutini) has been accepted by the European Medicines AgencyCoupled with the June 18 announcement that it has submitted a new drug listing application to the State Drug Administration, the park with 2 days 4 anti-cancer drugs of new progress, ran out to help Suzhou to build a "Chinese drug valley" of the "acceleration."Shandong Province selected, including Qingdao High-tech Industrial Development Zone, Jinan High-tech Industrial Development Zone, Zibo High-tech Industrial Development ZoneAmong them, Jinan high-tech industrial development zone ranked 10thGuangdong selected including Guangzhou High-tech Industrial Development Zone, Shenzhen High-tech Industrial Park, Dongguan Songshan Lake High-tech Industrial Development Zone, Foshan High-tech Industrial Development ZoneGuangzhou High-tech Industrial Development Zone, Shenzhen High-tech Industrial Park in the list are ranked in the top ten, respectively, ranked sixth and seventhfrom the list, you can also find that the regional distribution imbalance is seriousAmong them, the eastern region accounted for 60 seats in the biomedicine park, the central region accounted for 17 seats, the western region accounted for 15 seats, the northeast region accounted for 8 seats, in addition, compared with the new generation of parks, the old park because of the early start, good resources and other advantages, in the top 100 list of the position is more obviousIn the list of the top 100 biopharmaceutical industrial parks, the old park accounted for 62 seatsThe New Generation Campus has only 38 seats.